Stage 3 chronic kidney disease is remarkably common, especially among older adults. In the general U.S. adult population, roughly 7% have stage 3 or 4 CKD at any given time, a figure that has held fairly steady since the early 2000s.1PubMed Central. Trends in Prevalence of Chronic Kidney Disease in the United States Among people over 65, the picture is dramatically different: data from large databases put CKD prevalence in that age group at around 44%.2Clinical Kidney Journal. Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity What makes stage 3 CKD unusual as a chronic condition is the enormous gap between how many people have it and how many know they have it.
Prevalence Across Age Groups
Age is the single biggest predictor of stage 3 CKD, and the numbers climb steeply once you pass middle age. An analysis of older U.S. adults found that about 36% had stage 3 or greater CKD based on estimated kidney filtration rates, even though many of those people had normal-looking creatinine levels on standard blood tests.3PubMed Central. High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine That is not a typo: more than one in three older adults in that study met the laboratory criteria for stage 3 CKD. The reason is straightforward. After roughly age 60 to 65, kidney filtration naturally declines, and in a substantial share of people that decline crosses the threshold used to define stage 3.2Clinical Kidney Journal. Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity
In younger and middle-aged adults, stage 3 CKD is far less common. A U.S. study tracking trends over nearly two decades found that the combined prevalence of stages G1 through G3 rose from about 9% in 1999–2000 to around 14% by 2013–2014, then dipped slightly to about 13% by 2017–2018.4PubMed Central. Trends in the prevalence of Chronic Kidney Disease in the United States, 1999–2018 The most advanced stages, 4 and 5, remained rare at about 0.3% of the population. So while the overall CKD burden has grown, the increase is concentrated in the earlier stages, and much of it reflects better detection and an aging population rather than a sudden spike in kidney disease.
Who Is Most Likely to Have It
Beyond age, several demographic factors shape your risk. CKD is more prevalent in women, racial minorities, and people with diabetes or high blood pressure.5PubMed Central. Epidemiology of chronic kidney disease: an update 2022 An Austrian primary care analysis found stage 3–5 CKD in about 12% of women compared to 6% of men, roughly double the rate.6PubMed Central. Chronic kidney disease is more prevalent among women but more men than women are under nephrological care Paradoxically, despite having higher prevalence, women in that study were less likely to be under the care of a kidney specialist.
Racial disparities in the United States follow a complex pattern. A study estimating lifetime risk from birth found that white women had the highest overall chance of reaching stage 3a or beyond, at about 65%, while white men and Black men had similar lifetime risks of about 52–54% for stage 3a. But Black Americans face an earlier onset of kidney disease and a much higher lifetime risk of the more severe stages. By age 60, about 10% of Black men and Black women had already reached stage 3a, compared with roughly 7–8% of white men and women. And for the most dangerous outcome, end-stage kidney failure requiring dialysis or transplant, the lifetime risk for Black men was about 8.5%, more than double the rate for white men.7American Journal of Kidney Diseases. Lifetime Incidence of CKD Stages 3-5 in the United States
Trends by race have also shifted over time. Among non-Hispanic white and non-Hispanic Black Americans, CKD prevalence rose through the early 2000s and then plateaued. Among Mexican American adults, prevalence was initially lower but nearly doubled between 2003–2004 and 2015–2016, converging with other groups.8JAMA Network Open. National Trends in the Prevalence of Chronic Kidney Disease Among Racial/Ethnic and Socioeconomic Status Groups, 1988-2016
The Staggering Awareness Gap
Perhaps the most striking fact about stage 3 CKD is how few people who have it realize they do. Stage 3 typically produces no symptoms. Your kidneys are working at roughly 30–59% of normal capacity, but you feel fine. A U.S. study tracking awareness over several years found that even after some improvement, only about 9% of people with stage 3 CKD knew they had it.9PubMed Central. Patient Awareness in Chronic Kidney Disease: Trends and Predictors People who also had diabetes, high blood pressure, or protein in their urine were more likely to be aware, but the baseline was so low that even “more likely” still meant most were in the dark.
The problem extends to doctors’ records, not just patients’ knowledge. A multinational study spanning Australia, Brazil, Canada, England, and Spain found that the vast majority of patients with laboratory evidence of stage 3 CKD had no CKD diagnosis recorded in their medical charts. In Canada, 92% of such patients were unrecorded; in Brazil, 97%.10International Journal of Clinical Practice. High Prevalence of Unrecorded Stage 3 Chronic Kidney Disease in Australia, Brazil, Canada, England, and Spain England fared best, but even there more than half lacked a recorded diagnosis. A similar pattern showed up in Italy, where among patients with lab results pointing to stage 3 CKD, only 5% had a CKD diagnostic code in their records.11Journal of Nephrology. Awareness and management of stage 3 chronic kidney disease among primary care practitioners in Italy
Several factors make stage 3 CKD easy to miss. Being female, having stage 3a rather than the more severe 3b, and lacking a history of diabetes or hypertension all increased the odds of going undiagnosed in a multinational analysis.12BMJ Open. Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA In other words, the people who look “healthiest” on paper are the ones most likely to slip through the cracks.
Why the Numbers Change Depending on the Formula
One reason prevalence estimates vary is that the equation used to estimate kidney function matters. Doctors do not measure your filtration rate directly. Instead, they plug a blood creatinine level, your age, and sometimes your sex and race into a mathematical formula. For years the standard was the MDRD equation; more recently, the CKD-EPI equation has been adopted. CKD-EPI tends to give slightly higher filtration estimates, particularly for people near the stage 2/stage 3 boundary.
In a large primary care population, switching from MDRD to CKD-EPI reclassified about 11% of people previously labeled stage 3 as stage 2, effectively removing them from CKD registers.13PubMed Central. Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting A screening study found that the MDRD equation produced a stage 3 prevalence of 11%, while the CKD-EPI equation yielded about 8% in the same group of people.14PubMed Central. MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? Another primary care study confirmed the pattern, with CKD-EPI generating estimates about 1.4 points higher on average, enough to bump some patients across the threshold.15British Journal of General Practice. Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification
This is not just a statistical curiosity. If you had a borderline result years ago under the older formula, you might have been told you had early stage 3 CKD. Under the newer formula, the same blood test could place you in stage 2, which is not considered CKD by many clinical guidelines. That does not mean your kidneys changed; the yardstick did. If your doctor has mentioned a stage 3 result, it is worth asking which formula was used and whether a repeat test still puts you in the same category.
What Stage 3 CKD Actually Means for Long-Term Health
A stage 3 diagnosis understandably alarms people, but the prognosis is more nuanced than the label suggests. For most older adults with stage 3, the biggest risk is not dialysis. A study of older CKD patients found they were about 13 times more likely to die of any cause than to progress to end-stage kidney failure, and about 6 times more likely to die of cardiovascular disease specifically than to reach end-stage disease.16PubMed Central. Chronic kidney disease and the risk of end-stage renal disease versus death In plain terms, most people with stage 3 CKD will never need dialysis. The condition is a marker of cardiovascular risk more than it is a guarantee of kidney failure.
Protein in the urine changes this calculus. Stage 3 is subdivided into 3a (filtration rate 45–59) and 3b (30–44), and the presence or absence of albuminuria, protein leaking into urine, substantially affects prognosis. Among patients with stage 3, about 16–17% had confirmed albuminuria in one study, while another roughly 6% had a different type of protein leak.17PubMed Central. Assessment of Proteinuria in Patients with Chronic Kidney Disease Stage 3: Albuminuria and Non-Albumin Proteinuria If you have stage 3a with no protein in your urine, your risk of progression is low. Stage 3b with significant proteinuria is a different story and typically warrants closer monitoring.
The Role of Diabetes, High Blood Pressure, and Weight
Diabetes and hypertension are the two conditions most strongly tied to stage 3 CKD. In primary care settings, more than a quarter of patients with diabetes and about a fifth of those with hypertension had CKD.18PubMed Central. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice A U.S. study found that the link between hypertension and stage 3–4 CKD was strongest in younger adults, where those with high blood pressure had roughly double the prevalence of CKD compared to those without. The association weakened with age, likely because so many older adults develop reduced kidney function regardless.19PubMed Central. Age-related associations of hypertension and diabetes mellitus with chronic kidney disease A similar pattern held for diabetes: the risk ratio was about three-fold in younger adults but shrank in older groups.
Obesity adds its own layer of risk, though the picture gets complicated. Data from the Framingham Heart Study showed that obese individuals had about 68% higher odds of developing stage 3 CKD in a basic analysis, but that increase became statistically insignificant once researchers accounted for other factors like blood pressure and blood sugar.20PubMed Central. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study A Chinese cohort study found that obesity combined with metabolic syndrome roughly tripled CKD risk, but obesity alone still raised risk, suggesting excess weight has some independent effect on the kidneys even when blood sugar and blood pressure look fine.21PubMed Central. Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort The metabolic cluster of high blood sugar, abnormal cholesterol, and elevated blood pressure that often accompanies obesity has been clearly linked to markers of kidney damage including reduced filtration and protein in the urine.22PubMed Central. Metabolic syndrome and chronic kidney disease: Current status and future directions
Global Variation in Prevalence
Stage 3 CKD is not distributed evenly around the world. A study comparing regions found that the age-standardized prevalence of CKD stages 3–5 ranged from about 5.5% to 10.4% in high-income countries, 7.6% to 13.7% in Central and Eastern Europe, and 7.4% to 13.1% in lower-income regions.23Kidney International Reports. Worldwide Disparity in the Relation Between CKD Prevalence and Kidney Failure Risk Higher prevalence in lower-income settings does not necessarily translate to higher rates of dialysis, because access to kidney replacement therapy is vastly unequal. In Africa, the median number of dialysis centers is less than one per million people, compared to about 18 per million in North America.24The Lancet. Third iteration of the International Society of Nephrology Global Kidney Health Atlas In those settings, people with advanced CKD may simply die without ever being counted as kidney failure patients.
The Financial Weight of Stage 3
Even at stage 3, the costs add up. In the U.S. Medicare population, the annual medical expenses attributable to CKD were about $3,500 per person at stage 3, jumping to roughly $12,700 at stage 4.25PubMed Central. Medical costs of CKD in the Medicare population A global analysis put mean annual direct costs for stage 3a patients at around $3,060, which quadrupled by stage 5 and then exploded once dialysis started: roughly $57,000 per year for hemodialysis.26PubMed Central. Global Economic Burden Associated with Chronic Kidney Disease Because stage 3 CKD affects so many people simultaneously, even moderate per-person costs add up to an enormous public health bill. The financial incentive to catch and manage CKD early, before it advances, is substantial.
Newer Medications That Slow Progression
Until recently, managing stage 3 CKD meant controlling blood pressure, keeping blood sugar in check, and monitoring. That picture has changed with the arrival of SGLT2 inhibitors, a class of drugs originally developed for diabetes that turned out to have protective effects on the kidneys independent of blood sugar control. These medications reduce pressure inside the kidney’s filtering units, slowing damage over time.27PubMed Central. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
Real-world data from a Japanese diabetes center showed that in patients with stage 3b–4 CKD, the annual decline in kidney function essentially stopped after starting an SGLT2 inhibitor. Before treatment, filtration was dropping by a median of 3.8 points per year; after treatment, the decline was roughly zero. Protein in the urine also dropped significantly.28PubMed Central. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4 That is a small, single-center study, but it aligns with larger clinical trials that led to regulatory approvals of SGLT2 inhibitors specifically for CKD, regardless of whether the patient has diabetes. For the millions of people sitting in stage 3, this represents the first drug class shown to meaningfully change the disease trajectory.
When Acute Kidney Injury Leads to Stage 3
Not everyone arrives at stage 3 CKD through a slow, decades-long decline. A single episode of acute kidney injury, whether from severe dehydration, a medication reaction, a major surgery, or a serious infection, can push someone into stage 3 even after their kidneys appear to recover. A study following patients who had fully recovered from acute kidney injury found that 15% went on to develop stage 3 CKD within a median follow-up of two and a half years, compared to only 3% of similar patients who never had the acute episode. Even after adjusting for other risk factors, the acute injury nearly quadrupled the risk of landing in stage 3.29PubMed Central. Association of complete recovery from acute kidney injury with incident CKD stage 3 and all-cause mortality If you have been hospitalized with a kidney injury in the past, follow-up kidney function testing is worth requesting even if you were told your kidneys bounced back.
Heat, Work, and Kidney Disease in Unexpected Places
In Central America, an epidemic of kidney disease has struck agricultural workers, many of them young men without the usual risk factors of diabetes or hypertension. Research increasingly points to chronic heat stress and dehydration as the primary driver. Workers exposed to extreme temperatures over repeated harvests show measurable declines in kidney function across a single work season, and long-term exposure leads to permanent damage.30PubMed Central. Chronic kidney disease of non-traditional origin in Mesoamerica: a disease primarily driven by occupational heat stress Studies on pesticides and infectious causes have largely come up empty, reinforcing the conclusion that heat and inadequate fluid intake are the central culprits.31PubMed Central. Occupational Heat Stress and Kidney Health: From Farms to Factories This form of CKD, sometimes called CKD of non-traditional origin, is a reminder that kidney disease is not just a problem of aging and metabolic disease. As global temperatures rise, occupational kidney damage may become relevant to outdoor workers well beyond the sugarcane fields of Central America.
Stage 3 CKD in Children
While CKD is overwhelmingly a disease of aging, it does occur in children, though at vanishingly low rates. A five-year analysis from South East England found that the mean prevalence of CKD stages 3–5 in children under 16 was about 90 per million children, with incidence nearly tripling over the study period from roughly 8 to 25 per million.32Archives of Disease in Childhood. The demographic characteristics of children with chronic kidney disease stages 3–5 in South East England over a 5-year period The causes in children are almost entirely different from those in adults: congenital abnormalities of the kidneys and urinary tract, inherited conditions, and childhood immune diseases rather than diabetes and hypertension. The rising incidence likely reflects better detection and referral patterns rather than a true increase in childhood kidney disease.